Deepcell

Deepcell is a private, venture-backed biotech company pioneering the field of 'morpholomics'—using AI to analyze and sort living cells based on their visual appearance. Its core product, the REM-i platform, integrates custom microfluidics, high-resolution imaging, and a self-supervised AI foundation model to provide a non-destructive, label-free workflow for single-cell analysis and enrichment. The company is targeting the research tools and diagnostics markets, with strategic partnerships in place, and appears to be in an early revenue stage as it commercializes its platform for academic and biopharma applications.

The REM-i platform integrates custom microfluidics for gentle cell handling, high-resolution live-cell imaging, and a self-supervised AI foundation model to analyze and sort viable cells based on morphology without labels.

Deepcell competes with established players in flow cytometry (e.g., BD, Beckman Coulter), high-content screening/imaging (e.g., Sartorius, Revvity), and single-cell analysis (e.g., 10x Genomics). Its key differentiator is the integrated, label-free, AI-driven workflow focused on live-cell morphology, a niche not fully addressed by incumbents.